Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After Measles-Mumps-Rubella Vaccine in the United States
Vitali Pool, Paul Gargiullo(Centers for Disease Control and Prevention), Gina T. Mootrey, Robert M. Jacobson(Mayo Clinic), John W. Yunginger, Robert T. Chen(The Task Force for Global Health), John M. Kelso(Scripps Health), M. Miles Braun(Center for Biologics Evaluation and Research)
Cited by 136
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Morbid Obesity as a Risk Factor for Hospitalization and Death Due to 2009 Pandemic Influenza A(H1N1) Disease
|PLoS ONE|2010|449
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448